We seek to focus the efforts of the global Alzheimer’s Disease and related dementias (ADRD) community along with digital health innovators in order to develop new digital measures. Digital measures provide value for speeding the development of effective new therapies and improving care management. A pre-competitive collaboration is essential to assemble the variety of needed expertise around these complex diseases. By convening a balanced and inclusive group of global multistakeholder experts, including patient, carepartner, clinician, clinical scientist, technological, regulatory, and payer experts, there is an opportunity to define global meaningful aspects of health and build consensus for a set of core digital clinical measures in ADRD at the intersection of technological capabilities and patient, carepartner, and clinical need.
This globally-acceptable core measure set will become the focus of digital measure development efforts in ADRD, preventing disparate and siloed efforts that yield limited progress, instead supporting directed innovation and competition that places the patient voice at the heart of drug development in ADRD and fuels progress in treating the heterogeneity of these complex diseases.
